期刊
ONCOIMMUNOLOGY
卷 1, 期 3, 页码 326-333出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.18852
关键词
regulatory T cell; antiangiogenic molecule; CCR4; chemokine
资金
- Canceropole Ile de France
- ANR (Agence Nationale de la Recherche)
- Ligue contre le Cancer
- Association pour la Recherche sur le Cancer
- Institut National du Cancer
- Centre d'investigation Clinique en Biotherapie [CIC-BT505]
- Labex Immuno-Oncology
CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb ...) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors, etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据